

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **ISPH-0755**
Inventors: **Dean and Murray**
Serial No.: **Not Yet Assigned**
Filing Date: **Herewith**
Examiner: **Not Yet Assigned**
Group Art Unit: **Not Yet Assigned**
Title: **Antisense Modulation of Transforming
Growth Factor- β Expression**

"Express Mail" Label No. **EV331020051US**

Date of Deposit **August 1, 2003**

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Commissioner for Patents, Mail Stop Sequence, P. O.
Box 1450, Alexandria, VA 22313-1450.

By (Signature)
Typed Name: **Jane Massey Licata, Reg. No. 32,257**

Commissioner for Patents
Mail Stop Sequence
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is set forth below; or
- () The fee of \$240.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- () Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/948,002 filed September 5, 2001 and 09/661,753, filed September 14, 2000, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: August 1, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. ISPH-0755	Serial No. Not yet assigned
		Applicant Dean and Murray	
		Filing Date Herewith	Group Not yet assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Arteaga et al., "Reversal of Tamoxifen Resistance of Human Breast Carcinomas <i>In Vivo</i> by Neutralizing Antibodies to Transforming Growth Factor- β ", 1999 <i>J. Nat. Cancer Inst.</i> 91, 46-53	
	AB	Hoffman et al., "Potential Role of TGF- β in Diabetic nephropathy", 1998 <i>Electrolyte Metab.</i> 24, 190-196	
	AC	Kim et al., "Inhibition of Wound-Induced Expression of Transforming Growth Factor- β 1 mRNA by its Antisense Oligonucleotides", 1998 <i>Pharmacol. Res.</i> 37, 289-293	
	AD	Kim et al., "Role of TGF- β 1 on the IgE-Dependent Anaphylaxis Reaction ¹ ", 1999 <i>J. Immunol.</i> 162 4960-4965	
	AE	Liu et al., "The Transcription Factor EGR-1 Suppresses Transformation of Human Fibrosarcoma HT1080 Cells by Coordinated Induction of Transforming Growth Factor- β 1, Fibronectin, and Plasminogen Activator Inhibitor-" " 1999 <i>J. Biol. Chem.</i> 274, 4400-4411	
	AF	Nakajima et al., "An Autocrine Function for Transforming Growth Factor (TGF)- β 3 in the Transformation of Atrioventricular Canal Endocardium into Mesenchyme during Chick Heart Development", 1998 <i>Japan Dev. Biol.</i> 194, 99-113	
	AG	Schüftan et al., " α_2 -Macroglobulin reduces paracrine-and autocrine-stimulated matrix synthesis of cultured rat hepatic stellate cells", 1999 <i>Eur. J. Clin. Invest.</i> 29, 519-528	
	AH	Shen et al., "Inhibition of Transforming Growth Factor- β 2 Expression with Phosphorothioate Antisense Oligonucleotides in U937 Cells", 1999 <i>Bioorg. Med. Chem.</i> 9, 13-18	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. ISPH-0755	Serial No. Not yet assigned
		Applicant Dean and Murray	
		Filing Date Herewith	Group Not yet assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AI	Tzai et al., "Antisense Oligonucleotide Specific for Transforming Growth of MBT-2 Factor- β 1 Inhibit Both <i>in Vitro</i> and <i>in Vivo</i> Growth of MBT-2 Murine Bladder Cancer", 1998 <i>Anticancer Res.</i> 18, 1585-1589	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0755	Serial No. Not yet assigned
	Applicant Dean and Murray	
	Filing Date Herewith	Group Not yet assigned

U. S. PATENT DOCUMENTS

Examiner		Document	Date	Name	Class	Subclass
	AA	5,683,988	11-4-97	Chung	514	44

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	AB	WO 94/26888	24-11-94	PCT	x	

EXAMINER

DATE CONSIDERED